New and Efficient Approach to Aryl Phosphoramidate Derivatives of AZT/d4T as Anti-HIV Prodrugs

Xueshu Li; Hua Fu; Yuyang Jiang; Yufen Zhao; Jinyong Liu

doi:10.1055/s-2004-834800

LETTER

New and Efficient Approach to Aryl Phosphoramidate Derivatives of AZT/d4T as Anti-HIV Prodrugs

Xueshu Li^a, Hua Fu*^a, Yuyang Jiang^a,b, Yufen Zhao^a, Jinyong Liu^a
^a The Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, Tsinghua University, Beijing 100084, P. R. China
^b The Key Lab of Chemical Biology, Guangdong Province, College of Shenzhen, Tsinghua University, Shenzhen 518057, P. R. China
Fax: +86(10)62781695; e-Mail: fuhua@mail.tsinghua.edu.cn;

Abstract

All articles of this category

Abstract

Ester exchange of diaryl phosphite with AZT or d4T produced aryl AZT/d4T H-phosphonate, and the following reaction with amino acid esters in the presence of hexachloroethane and triethylamine yielded membrane-soluble anti-HIV prodrugs aryl phosphoramide derivatives of AZT and d4T in good yields.

Key words

aryl phosphoramidate - anti-HIV - AZT - d4T

Full Text

References

1 Mitsuya H. Weinhold KJ. Furman PA. St. Clair MH. Nusinoff-Lehrman S. Gallo RC. Bolognesi D. Barry DW. Broder S. Proc. Natl. Acad. Sci., U.S.A. 1985, 82: 7096

2 Mitsuya H. Broder S. Proc. Natl. Acad. Sci., U.S.A. 1986, 83: 1911

3 Balzarini J. Kang GJ. Dalal M. Herdewijn P. De Clercq E. Broder S. Johns DG. Mol. Pharmacol. 1987, 32: 162

4 Herdewijn P. Balzarini J. De Clercq E. Pauwels R. Baba M. Broder S. Vanderhaeghe H. J. Med. Chem. 1987, 30: 1270

5 Balzarini J. Baba M. Pauwels R. Herdewijn P. De Clercq E. Biochem. Pharmacol. 1988, 37: 2847

6 Jones RJ. Bischofberger W. Antiviral Res. 1995, 27: 1

7 Meier C. Synlett 1998, 233

8 McGuigan C. Devine KG. Connor TJ. Galpin SA. Jeffries DJ. Kinchington D. Antiviral Chem. Chemother. 1990, 1: 107

9 Farrow SN. Jones AS. Kumar A. Walker RT. Balzarini J. De Clercq E. J. Med. Chem. 1990, 33: 1400

10 Balzarini J. Cooney DA. Dalal M. Kang GJ. Cupp JE. De Clercq E. Broder S. Johns DG. Mol. Pharmacol. 1987, 82: 798

11 Starnes MC. Cheng YC. J. Biol. Chem. 1987, 262: 988

12 Hao Z. Cooney DA. Farquhar D. Perno CF. Zhang K. Masood R. Wilson Y. Hartman NR. Balzarini J. Johns DG. Mol. Pharmacol. 1990, 37: 157

13 Johnson MA. Ahluwajia G. Connelly MC. Cooney DA. Broder S. Johns DG. Fridland A. J. Biol. Chem. 1998, 263: 15354

14 Johnson MA. Fridland A. Mol. Pharmacol. 1989, 36: 291

15 Perno CF. Yarchoan R. Cooney DA. Hartman NR. Webb DSA. Hao Z. Mitsuya H. Johns DG. Broder S. J. Exp. Med. 1989, 169: 933

16 McGuigan C. Pathirana RN. Balzarini J. De Clercq EJ. J. Med.Chem. 1993, 36: 1048

17 Venkatachalam TK. Tai HL. Vig R. Chen CL. Jan ST. Uckun FM. Bioorg. Med. Chem. Lett. 1998, 8: 3121

18 Jones RJ. Bishofberger N. Antiviral Res. 1995, 27: 1

19 Stang SL. Meier R. Rocaboy C. Gladysz JA. J. Fluorine Chem. 2003, 119: 141

20 Walsh EN. J. Am. Chem. Soc. 1959, 81: 3023

21

Analytical data of representative compound 9ae [2′,3′-dideoxy-2′,3′-didehydrothymidine 5′-(phenyl methoxy-phenylalaninyl phosphate)]: ¹³P NMR (121 MHz, CDCl₃): δ = 3.30, 3.70 (a pair of diastereomers, ratio of peak area = 4:6) ppm. ¹H NMR (300 MHz, CDCl₃): δ = 1.78 (s, 3 H, 5-Me), 2.94-2.99 (m, 2 H, CH₂Ph), 3.64 (s, 3 H, OMe), 3.84-4.19 (m, 4 H, Phe-CH, Phe-NH, 2H-5′), 4.89 (m, 1 H, H-4′), 5.82-5.88 (m, 1 H, H-3′), 6.20-6.29 (m, 1 H, H-2′), 7.12-7.27 (m, 12 H, 2 Ph, H-1′, H-6), 9.43 (s, 1 H, NH) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 12.21 (C5), 40.30 (CH₂Ph), 52.29 (OCH₃), 55.45, 55.73 (Phe-CH), 66.20, 66.87 (C-5′), 84.36, 84.58 (C-4′), 89.42, 89.67 (C-1′), 111.20, 111.31 (C5), 119.91, 119.98 (OPh-ortho), 125.06 (OPh-para), 127.11, 127.21 (C-2′), 128.49, 129.34, 129.63 (CH₂ Ph), 129.34, 129.63 (OPh-meta), 133.18-133.50 (C-3′), 135.46 (6-C), 150.18, 150.29 (OPh-ipso), 150.86 (C2), 163.84 (C4), 172.72 (Phe-CO). ESI-MS: m/z = 542 [M + H]⁺, 564 [M + Na]⁺.

22 Georgiev EM. Kaneti J. Troev K. Roundhill DM. J. Am. Chem. Soc. 1993, 115: 10964